NCT04987996撤回2 期
Randomized Double-Blind Placebo Controlled Phase II Study of a Galectin Inhibitor (GR-MD-02) and Pembrolizumab Versus Pembrolizumab and Placebo in Patients With Metastatic Melanoma and Head and Neck Squamous Cell Carcinoma
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 撤回
- 试验地点
- 1
- 主要终点
- Overall response rate based on disease imaging
研究概览
简要总结
The purpose of this study is to test the safety & efficacy of combination drugs versus placebo to treat metastatic melanoma and head and neck squamous cell carcinoma.
详细描述
Eligible patients will be registered, stratified by diagnosis (melanoma versus OHN cancer), and the number of prior systemic therapies, and randomized to receive either GR-MD-02 + pembrolizumab or pembrolizumab + placebo.
In addition to monitoring for toxicity and clinical response, blood and tumor samples will be obtained to assess immunologic measures relevant to galectin biology and pembrolizumab T-cell checkpoint inhibition.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Patients with unresectable or metastatic melanoma including unknown primary, mucosal or uveal melanomas. Histological confirmation of melanoma will be required by previous biopsy or cytology. Patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) with disease progression during or after platinum-containing chemotherapy are eligible. PD-L1 testing is not needed for OHN cancers.
- •Patients who have received anti-PD1 or anti-PD-L1 in the past are eligible if it has been at least 6 months since the last anti-PD-1 or PD-L1 dose, they meet all other eligibility criteria and progression of malignancy has been documented on imaging. Progression for this patient subset is defined as the appearance of one or more new metastatic sites, or a 5% or greater increase in the sum of diameter of target lesions or an unequivocal increase in non-target site. Treatment naïve melanoma patients are eligible.
- •Patients must be ≥ 18 years of age.
- •ECOG performance status of 0-
- •Women of childbearing potential must have a serum or urine pregnancy test performed within 72 hours prior to the start of protocol treatment. The results of this test must be negative in order for the patient to be eligible. In addition, women of childbearing potential as well as male patients must agree to take appropriate precautions to avoid pregnancy.
- •No active bleeding.
- •Anticipated lifespan greater than 12 weeks.
- •Patients must sign a study-specific consent document.
排除标准
- •Patients who have previously received a galectin antagonist.
- •Patients with active autoimmune disease except for autoimmune thyroiditis or vitiligo (see Appendix C).
- •Patients with history of autoimmune colitis.
- •Patients with untreated brain metastases. Patients with treated brain metastases who demonstrate control of brain metastases with follow-up imaging 4 or more weeks after initial therapy are eligible.
- •Patients requiring other systemic oncologic therapy, including experimental therapies.
- •Patients with active infection requiring antibiotics.
- •Pregnant or lactating women, as treatment involves unforeseeable risks to the embryo or fetus.
- •Need for steroids at greater than physiologic replacement doses. Inhaled corticosteroids are acceptable.
- •Laboratory exclusions (to be performed within 28 days of enrollment):
- •WBC < 3.0 x 109/L
- •Hgb < 9.0 g/dL
- •AST or ALT > 1.5 times ULN
- •Total bilirubin > 1.9 g/dL, unless due to Gilbert's Syndrome. If Gilbert's Syndrome is present by clinical history, then direct bilirubin must by < 3.0 g/dl.
- •Known history of HIV
- •Known history of Hepatitis B
- •Known history of Hepatitis C
- •INR > 1.5x ULN
- •Inability to give informed consent and comply with the protocol. Patients must be judged able to understand fully the investigational nature of the study and the risks associated with the therapy.
- •Any medical condition that in the opinion of the Principal Investigator would compromise the safety or conduct of the study procedures.
- •Unresolved immune-mediated pneumonitis, diarrhea, elevation of hepatocellular enzymes or other toxicities requiring greater than physiological replacement doses of steroids.
研究组 & 干预措施
GR-MD-02 + pembrolizumab
Experimental
4 mg/kg GR-MD-02 in combination with standard pembrolizumab treatment.
干预措施: GR-MD-02 (Drug)
GR-MD-02 + pembrolizumab
Experimental
4 mg/kg GR-MD-02 in combination with standard pembrolizumab treatment.
干预措施: Pembrolizumab (Drug)
Pembrolizumab Monotherapy
Placebo Comparator
4 mg/kg placebo in combination with standard pembrolizumab treatment.
干预措施: Placebo (Drug)
Pembrolizumab Monotherapy
Placebo Comparator
4 mg/kg placebo in combination with standard pembrolizumab treatment.
干预措施: Pembrolizumab (Drug)
结局指标
主要结局
Overall response rate based on disease imaging
时间窗: From date of randomization until the date of first documented progression, assessed up to 63 weeks.
Determine the objective response of GR-MD-02 + pembrolizumab versus pembrolizumab monotherapy in patients with advanced MM or HNSCC
次要结局
- Evaluation of predictive biomarker(Day 85)
- Evaluation of GAL-3 expression(Screening and Day 68)
- Frequency of Immune-mediated adverse events(From time of informed consent to week 63)
- Evaluation of antiviral immunity(Day 85)
研究者
研究点 (1)
Loading locations...
相似试验
撤回
2 期
Leidos-Enabled Adaptive Protocol for Clinical Trials (LEAP-CT) in Hospitalized Patients With COVID-19 (Addendum 1)2019 Novel Coronavirus Disease2019 Novel Coronavirus Infection2019-nCoV Disease2019-nCoV InfectionCOVID-19 PandemicCOVID-19 Virus DiseaseCOVID-19 Virus InfectionCovid19Coronavirus Disease 2019SARS-CoV-2 InfectionSARS-CoV-2 Acute Respiratory DiseaseCOVID-19NCT05085574Leidos Life Sciences
已完成
2 期
Treatment of Cognitive Impairment in Men With Schizophrenia (MK5757-005)(COMPLETED)SchizophreniaNCT00848484Merck Sharp & Dohme LLC54
已完成
2 期
NGU: Doxycycline (Plus or Minus Tinidazole) Versus Azithromycin (Plus or Minus Tinidazole)UrethritisNCT00322465National Institute of Allergy and Infectious Diseases (NIAID)305
已完成
1 期
Safety and Efficacy Trial of DNA Vaccines to Treat Genital Herpes in AdultsGenital Herpes Simplex Type 2NCT02030301Vical165
已完成
1 期
A Study to Determine the Safety, Drug Levels and Drug Effects of BMS-986196 and Food and Formulation Effects on Relative Absorption Healthy ParticipantsHealthy ParticipantsNCT04882150Bristol-Myers Squibb102